

1

2

3

**Identification of a type IV secretion substrate of *Brucella abortus* that  
participates in the early stages of intracellular survival**

4

5

6

**Peter H. Döhmer<sup>1</sup>, Ezequiel Valguarnera, Cecilia Czibener<sup>1\*</sup> and Juan E.**

7

**Ugalde<sup>1\*</sup>**

8

9

10 **1** Instituto de Investigaciones Biotecnológicas “Dr. Rodolfo A. Ugalde”, Instituto  
11 Tecnológico de Chascomús, IIB-INTECH, CONICET, Universidad Nacional de San  
12 Martín, San Martín, Buenos Aires, Argentina.

13

14

15 **Running title: A novel *Brucella virB* secretion substrate**

16

17 **\* Corresponding authors**

18 **Mailing address**

19 Instituto de Investigaciones Biotecnológicas “Dr. Rodolfo A. Ugalde”, IIB-INTECH  
20 Universidad Nacional de San Martín. Avda 25 de Mayo y Francia, Campus  
21 Miguelete, UNSAM, San Martín (1650), Buenos Aires, Argentina.

22 Phone: (54)11-4006-1500 (2129 or 2135)

23 Fax: (54)11-4006-1559

---

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cmi.12224

Accepted Article

26 **SUMMARY**

27

28 *Brucella abortus*, the etiological agent of bovine brucellosis, is an intracellular  
29 pathogen whose virulence is completely dependent on a type IV secretion system.  
30 This secretion system translocates effector proteins into the host cell to modulate the  
31 intracellular fate of the bacterium in order to establish a secure niche where it actively  
32 replicates. Although much has been done in understanding how this secretion system  
33 participates in the virulence process, few effector proteins have been identified to  
34 date. We describe here the identification of a type IV secretion substrate (SepA) that  
35 is only present in *Brucella* spp. and has no detectable homology to known proteins.  
36 This protein is secreted in a *virB* dependent manner in a two-step process involving a  
37 periplasmic intermediate and secretion is necessary for its function. The deletion  
38 mutant showed a defect in the early stages of intracellular replication in professional  
39 and non-professional phagocytes although it invades the cells more efficiently than  
40 the wild type parental strain. Our results indicate that, even though the mutant was  
41 more invasive, it had a defect in excluding the lysosomal marker Lamp-1 and was  
42 inactivated more efficiently during the early phases of the intracellular life cycle.

43

## 44 INTRODUCTION

45

46 Intracellular pathogens have evolved a variety of strategies to survive and multiply  
47 within the host cells. These mechanisms are very versatile and in many cases involve  
48 specialized secretion systems devoted to the secretion and translocation of effector  
49 proteins to the host cell that interfere or modulate the cellular response to favor the  
50 infectious process (Cossart *et al.*, 2010, Ninio *et al.*, 2007). *Brucella* spp are gram-  
51 negative facultative intracellular bacteria that cause brucellosis, a wide spread  
52 zoonosis that affects mainly domestic animals and humans, causing important  
53 economical and sanitary problems in many areas of the world (Corbel, 1997,  
54 Godfroid *et al.*, 2011). One of the hallmarks of the infectious cycle of *Brucella* is its  
55 ability to survive and multiply in professional phagocytes like macrophages (Atluri *et*  
56 *al.*, 2011), a process that requires the *virB* system, a type IV secretion system  
57 homologous to the *Agrobacterium tumefaciens* conjugation-like system that  
58 translocates the T-DNA into the plant cell (Alvarez-Martinez *et al.*, 2009). This  
59 secretion system is necessary to modulate the intracellular trafficking of the bacteria  
60 in the host cell. In the early phases this system contributes to avoid the fusion of the  
61 *Brucella* containing vacuole (BCV) with the lysosomes and, in a second phase,  
62 redirects its fate to a calnexin-positive endoplasmic reticulum derived membrane  
63 niche where it can actively replicate (Celli *et al.*, 2003, Comerci *et al.*, 2001). The  
64 intracellular traffic of *Brucella* in non-professional and professional phagocytes has  
65 been extensively studied (Celli *et al.*, 2003, Celli *et al.*, 2005, Comerci *et al.*, 2001,  
66 Pizarro-Cerda *et al.*, 1999, Pizarro-Cerda *et al.*, 1998). Shortly after its internalization,  
67 the BCV transiently acquires the lysosomal marker Lamp-1, which is subsequently  
68 excluded as the BCV is directed to its final replicative organelle. The BCV actively

69 excludes the mature lysosomal marker Cathepsin-D, avoids maturation into an active  
70 lysosome and acquires endoplasmic reticulum derived membranes creating a suitable  
71 organelle for the replication of the bacteria.

72 Although much has been done on how the *virB* system affects the intracellular  
73 trafficking, the virulence process, and how this complex secretion system is  
74 transcriptionally regulated (Arocena *et al.*, 2010, Arocena *et al.*, 2012, Delrue *et al.*,  
75 2005, Sieira *et al.*, 2010, Sieira *et al.*, 2012, Sieira *et al.*, 2004), very little is known on  
76 the identity of the secreted/translocated proteins as well as the molecular mechanisms  
77 they use to modulate the intracellular trafficking. To date eleven effectors have been  
78 identified and, of them, the activity of only one has been elucidated.

79 RicA was identified as a *Brucella* protein that interacts with the GTPase Rab2 and is  
80 translocated into the host cell in a *virB* dependent manner. This effector protein binds  
81 preferentially the GDP-bound Rab2, avoids the recruitment of this Rab to the BCV  
82 and affects the normal intracellular trafficking (de Barsy *et al.*, 2011). An interesting  
83 observation made by the authors of this report is that, even though RicA is  
84 translocated into the host in a *virB* dependent manner, the protein is also secreted into  
85 the supernatant in bacteriological cultures in a *virB* independent manner, suggesting  
86 that there could be a different secretion system involved in this process. This raises the  
87 interesting point if the *virB* dependent translocation of effector proteins involves a  
88 two-step process with other secretion systems also participating.

89 Two effector proteins that were isolated identifying promoter regions similar to the  
90 *virB* promoter box are VceA and VceC. The authors of this report demonstrated,  
91 using a TEM1  $\beta$ -lactamase reporter, that these proteins are translocated into the host  
92 cells in a *virB* dependent manner and, in one of these proteins (VceE), a C-terminal

93 type four secretion signal was identified that is also functional in *Legionella* (de Jong  
94 *et al.*, 2008).

95 Recently, Marchesini *et al.* performed a bioinformatic and biochemical screening  
96 searching for novel *virB* effector proteins (Marchesini *et al.*, 2011). They identified,  
97 using as a reporter the adenylate cyclase (Cya) from *Bordetella pertussis*, four new  
98 *virB* dependent translocated proteins. One of these proteins, Bab2\_0123, was also  
99 detected as secreted in a *virB* dependent manner by immunofluorescence and  
100 biochemical fractionation. The authors demonstrated that the first 25 amino acids of  
101 the protein are necessary for translocation into the host cell and showed that the  
102 mutant had no detectable phenotype.

103 Very recently Myeni *et al.* (Myeni *et al.*, 2013) informed the identification of five  
104 new type IV effector proteins in *B. abortus*. The authors identified these proteins  
105 through a bioinformatic search and verified that they are translocated into the host  
106 cells using  $\beta$ -lactamase and CyaA adenylate cyclase reporter assays. The ectopic  
107 expression of several of them as well as single and combined deletion mutant strains  
108 indicate that *Brucella* modulates the secretory pathway using multiple effector  
109 proteins (Myeni *et al.*, 2013).

110 We describe here the identification of a *virB* secretion substrate present in all *Brucella*  
111 species sequenced to date. We demonstrate by immunofluorescence that this protein  
112 is secreted in a *virB* dependent manner during the infection of host cells and that this  
113 secretion requires a periplasmic intermediate. We also show that the mutant strain has  
114 a significant defect in the early stages of the intracellular multiplication process and  
115 that is less effective in excluding the lysosomal marker Lamp-1. Surprisingly, even  
116 though the mutant strain is more efficiently inactivated during the first stages of the  
117 intracellular replication process, it invades the host cell more efficiently than the wild

118 type suggesting that this gene might play a role in "selecting" the phagocytosis route  
119 and, thus, modulating the final destination of the resulting phagosome. This  
120 hypothesis is discussed.

121

122

123 **RESULTS**

124

125 **Identification of the gene product of Bab1\_1492 as a secreted protein in *Brucella***

126 ***abortus***

127 In order to identify novel virulence factors in *B. abortus* we performed a

128 bioinformatic search seeking for potential horizontally transmitted regions identifying

129 transposases or recombinases close to transfer tRNAs. This rationale is based on the

130 observation that, in many bacteria, horizontally transmitted pathogenic islands are

131 located adjacent to tRNAs and encode enzymes involved in DNA processing. For this

132 we used the program ARTEMIS (Rutherford *et al.*, 2000) and searched both *Brucella*

133 *abortus* 2308 chromosomes for putative transposases or recombinases that were

134 adjacent to genes coding for transfer tRNAs. Using this approach we identified

135 several potentially horizontally transmitted regions and analyzed each one of them

136 individually identifying the open reading frames and determining, for each,

137 conservation among *Brucella* species, presence in other bacteria and domain

138 structure. This methodology allowed us to select a group of potential proteins whose

139 genes were cloned upstream of a 3xFLAG, subcloned in a *Brucella* replicative vector

140 (pBBR1MCS-4) and introduced into a wild type *B. abortus* 23208 strain. The

141 resulting clones were used to infect J774 A.1 cells and, at different times post-

142 infection, the infected cells fixed and stained to detect the FLAG epitope and the

143 bacteria. The objective of this approach was to identify gene products secreted by the

144 bacteria during the infection of host cells. Figure 1A shows a schematic representation

145 of the screening method utilized. Out of 5 candidates analyzed one was detected on

146 the surface of the intracellular bacteria. Figure 1B shows that the protein product of

147 the gene Bab1\_1492 was detected on the bacterial surface during the infection of J774



148 A.1 cells but not the protein product of gene Bab1\_0740 (Figure 1C) although both  
149 genes were expressed (Figure 1D). To further examine the secretion of the protein  
150 product of Bab1\_1492, confocal images were obtained at 4 hrs post-infection and as a  
151 positive control a strain expressing a 3xFLAG fusion to the type IV effector Bpe123  
152 was used (Marchesini *et al.*, 2011). Figure 2A shows that at 4 hrs surface exposed  
153 Bab1\_1492 was observed in most of the bacteria analyzed, while only 15 to 20 % of  
154 bacteria were positive for Bpe123 as has been informed (Del Giudice *et al.*, 2013,  
155 Marchesini *et al.*, 2011) (Figure 2B). A scanning of the fluorescence in both channels  
156 through a liner path indicated that both marks showed the same pattern (Figure 2D).  
157 These results demonstrate that the protein product of Bab1\_1492 is secreted during  
158 infection, for this reason we named the gene *sepA* for Secreted Effector Protein A.

159

#### 160 **Secretion of SepA is a two-step *virB* dependent process**

161 Because the type IV secretion system (*virB*) is one of the main virulence traits  
162 required for intracellular survival we asked if secretion of SepA was dependent on  
163 this system. For this we introduced the plasmid carrying the FLAG-tagged version of  
164 *sepA* in the *virB10* and *virB11* mutant strains and determined the number of  
165 intracellular bacteria displaying the protein on the surface. As can be observed in  
166 Figure 3A and 3B, secretion of SepA was significantly reduced in the *virB* mutant  
167 backgrounds measured as the number of bacteria showing surface exposed FLAG  
168 staining, although expression of the tagged protein was equivalent between strains  
169 (Figure 3C). To determine if SepA is secreted immediately after internalization we  
170 analyzed by immunofluorescence surface exposed SepA in the wild type and the  
171 *virB10* mutant at 30 min post-infection. The results shown in Supplementary Figure 1  
172 showed that SepA is secreted very early during infection and in a *virB* dependent

173 manner. Altogether, these results demonstrate that secretion of SepA is dependent on  
174 a functional *virB* system.

175 It has been informed that some type IV secretion substrates possess a canonical sec-  
176 dependent secretion signal that targets them to the periplasm or the inner membrane  
177 as a first secretion step (Burns, 2003, Nagai *et al.*, 2001, Pantoja *et al.*, 2002). Since  
178 the analysis of the protein product of *sepA* using different prediction programs for the  
179 detection of putative sec-dependent secretion signals were not conclusive, we decided  
180 to determine if this protein is targeted to the periplasm and, if so, if this intermediate  
181 state is necessary for the *virB* secretion. To test we generated a double-tagged strain  
182 carrying a chromosomal FLAG-tagged version of the gene Bab2\_0448 coding for a  
183 cytoplasmic tellurite resistant protein that we are currently studying in the laboratory  
184 (unpublished results) in which we introduced the plasmid coding the *sepA*-3xFLAG.  
185 This strain was used to produce periplasmic and cytoplasmic fractions (see  
186 Experimental procedures) and the presence of SepA was determined in these  
187 fractions. As control proteins we used the presence of the protein product of  
188 Bab2\_0448 and GroEL for cytoplasm and OMP1 for periplasm. As can be seen in  
189 Figure 4A, SepA was found partitioned in both the periplasm and the cytoplasm as  
190 was OMP1, while the cytoplasmic controls were only detected in the corresponding  
191 fraction (cytoplasmic). This result demonstrates that SepA is exported to the  
192 periplasm. In order to determine if this periplasmic intermediate is required for the  
193 *virB* secretion we analyzed the bacterial surface display of the construct lacking the  
194 first 25 amino acids of the protein ( $\Delta$ N-SepA). As shown in Figure 4B, deletion of the  
195 amino terminal secretion signal abolished the surface display of SepA as did the  
196 absence of the *virB* system. Loading controls indicated that the deleted protein was  
197 expressed with lower levels than the wild type and that it migrated slightly less

198 (Figure 4C). We do not have an explanation for this puzzling observation but  
199 speculate that maybe the truncated protein, because it cannot be transported to the  
200 periplasm, aggregates or associates with other proteins resistant in our gel conditions.  
201 In order to determine if in the *virB* mutant background SepA is still present in the  
202 periplasm we performed a periplasmic extraction with the *virB10* and *virB11* strains  
203 expressing the SepA-3xFLAG fusion protein and determined the fractionation pattern  
204 of SepA in these strains. As can be observed in Figure 4D, SepA was found in the  
205 periplasm of these strains indicating that, even though it was not secreted to the  
206 bacterial surface, it retained a periplasmic localization. This result also demonstrates  
207 that the bacterial surface display of SepA is not the consequence of “leakage” of the  
208 periplasm of the extracellular space. Altogether these results indicate that SepA is  
209 targeted to the periplasm and that this intermediate state is required for the *virB*  
210 secretion.

211

### 212 **SepA participates in the early stages of intracellular replication**

213 To determine if *sepA* plays a role during the intracellular life cycle we generated a  
214 clean deletion strain and analyzed the intracellular multiplication in HeLa, J774 A.1  
215 cells and bone marrow derived macrophages (BMDM) with an antibiotic protection  
216 assay as described in Experimental procedures. As can be observed in Figure 5A, 5B  
217 and 5C the strain  $\Delta sepA$  showed a significant reduction in the intracellular CFU at 4  
218 and 24 hrs post-infection in both professional and non-professional phagocytes. At 48  
219 hrs, even though the mutant had less viable counts than the wild type strain, the  
220 differences were less dramatic in HeLa and J774 A.1 cells indicating that the mutant  
221 had a defect in the early stages of the intracellular replication process but was able to  
222 replicate. In BMDM the mutant was unable to replicate at 48 hr post-infection

223 indicating that the phenotype was more pronounced in these cells. The defects  
224 observed were not the consequence of a general replication phenotype as the mutant  
225 had an *in vitro* growth identical to the wild type parental strain (Figure 5D). To  
226 determine if the phenotype observed at 4 hrs post-infection was dependent on the  
227 multiplicity of infection (m.o.i.) we carried out an antibiotic protection assay on J774  
228 A,1 cells with different multiplicity of infections and determined intracellular CFUs at  
229 that time point. The results indicated that the  $\Delta sepA$  phenotype was not m.o.i.  
230 dependent (Figure 5E). As expected, we were unable to complement the  $\Delta sepA$   
231 mutant with the construction lacking the N-terminal periplasmic localization region  
232 indicating that the phenotype is dependent on the secretion of the protein (Figure 5F).  
233 The lower viable bacteria at 4 hrs post-infection could be result of a defect in the  
234 invasion or early intracellular survival. To discern between these possibilities, we  
235 initially determined the invasion capacity as described in Experimental procedures.  
236 The results, shown in Figure 6 indicated that invasion was not decreased in the mutant  
237 strongly suggesting that the defect was probably due a defect in the capacity to avoid  
238 the fusion of the BCV with the lysosomes. Moreover, an interesting observation was  
239 that, even though at 4 hrs post-infection the  $\Delta sepA$  mutant showed a 10-fold reduction  
240 in the intracellular bacteria, it actually invaded the host cells more efficiently than the  
241 wild type (Figure 6C). To determine if at early time points the internalized bacteria  
242 were viable, we performed a gentamicin protection assay and recovered intracellular  
243 bacteria at 1, 2, 3 and 4 hrs post-infection and found that at all times tested the mutant  
244 had less viable counts (Figure 6D) that decreased over time in comparison to the wild  
245 type strain. These results strongly suggested that the mutant probably had a defect in  
246 the early stages of the intracellular trafficking. To test this we determined the co-  
247 localization of the lysosomal marker Lamp-1 with the BCV at 4 and 24 hrs post-

248 infection in HeLa cells as described in Experimental procedures. As shown in Figure  
249 7A and 7B, the BCV containing the  $\Delta sepA$  mutant acquired the lysosomal marker  
250 Lamp-1 as the wild type at 4 hrs post-infection but was less efficient in excluding it at  
251 24 hrs suggesting a defect in avoiding the maturation into an active lysosome. Even  
252 though the strain  $\Delta sepA$  showed a defect in the initial phases of the intracellular life  
253 cycle the bacteria that were able to bypass this initial attack and replicated in an ER-  
254 like calnexin positive niche confirming that the defect was restricted to the initial  
255 phases of the intracellular cycle (data not shown).

256

257  **$\Delta sepA$  has no impact in the virulence in mice but over-expression of the gene**  
258 **causes a severe defect**

259 To determine if *sepA* plays a role in the virulence in the mouse model of infection, we  
260 infected intraperitoneally groups of five mice with the wild type 2308, the  $\Delta sepA$  and  
261 the complemented strains and measured, at 15 days post-infection, the bacterial load  
262 in the spleens. As can be seen in Figure 8A, the mutant strain did not display any  
263 differences in the CFUs per spleen in comparison to the parental strain. An interesting  
264 observation was that the complemented strain colonized the spleens significantly less  
265 than the mutant and the parental strains suggesting that over-expression of the gene  
266 might cause a negative effect. To confirm this we introduced plasmid pBBR1-MCS4/  
267 F2-3xF over-expressing SepA in the wild type 2308 strain and evaluated its virulence  
268 in mice in comparison with the non-transformed wild type and the deletion strains. As  
269 can be observed in Figure 8B, over-expression of SepA dramatically reduced the  
270 bacterial load in the spleens of infected mice at 15 days post-infection and the mutant,  
271 as indicated before, was as virulent as the wild type parental strain. This effect was  
272 not the consequence of a defect in the viability of the strain as the strain grew as the

273 parental strain (Supplementary Figure 2) and did not show any major membrane  
274 alterations evidenced by several indicators as for example LPS integrity (Figure 8C).  
275 These results strongly suggest that the expression of *sepA* is probably highly regulated  
276 and that an excess of the protein is detrimental for the virulence process although  
277 more work should be performed in order to understand the molecular basis of this  
278 defect.

279

## 280 DISCUSSION

281

282 Many intracellular pathogens have, as virulence strategies, the capacity to establish  
283 their multiplication niches inside professional phagocytes. To achieve this they have  
284 evolved complex secretion systems devoted to secrete and translocate into the host  
285 cells virulence factors that modulate the biological functions in their one benefit.  
286 Understanding at the molecular level this biochemical crosstalk has been one of the  
287 main focuses of the microbial pathogenesis field of the last decade. *Brucella*, the  
288 causative agent of Brucellosis, is an intracellular pathogen that replicates in  
289 macrophages and dendritic cells. The *virB* operon encodes one of the central virulence  
290 traits required for the intracellular lifestyle of the bacterium. This operon codes for a  
291 type IV secretion system responsible for the translocation of effector proteins that  
292 actively avoid the fusion of the *Brucella* containing vacuole with the lysosomes and  
293 recruit membranes from the endoplasmic reticulum to establish a competent  
294 replication niche (Celli *et al.*, 2003, Commerci *et al.*, 2001, O'Callaghan *et al.*, 1999,  
295 Sieira *et al.*, 2000). This macromolecular apparatus is essential for virulence and, to  
296 date, few secretion substrates have been identified (de Barys *et al.*, 2011, de Jong *et*  
297 *al.*, 2008, Marchesini *et al.*, 2011). We identify here a new virulence factor in  
298 *Brucella abortus* that is secreted in a *virB* dependent manner and we have named this  
299 gene *sepA*. We demonstrate by immunofluorescence that secretion of SepA occurs  
300 during the early phases of the intracellular life cycle of *B. abortus*, that this secretion  
301 is *virB* dependent and show that it involves a periplasmic intermediate. To date it is  
302 not clear the exact mechanism in type IV secretion systems. Even though it is highly  
303 accepted that secretion is a process in which the substrate is engaged in the cytoplasm,  
304 there have been reports of periplasmic and membrane proteins that are secreted in a

305 type IV dependent process in some pathogens (Burns, 2003, Nagai *et al.*, 2001,  
306 Pantoja *et al.*, 2002). One of the canonical examples of these is the pertussis toxin,  
307 that assembles in the periplasm and is secreted in a type IV dependent manner (Burns,  
308 2003). In the case of SepA we have clearly established that secretion to the surface of  
309 the bacteria is a process that depends on the *virB* system and on an N-terminal signal  
310 peptide that targets the protein to the periplasm indicating that its secretion is a two-  
311 step process. With the purpose of determining the role of *sepA* in the pathogenesis of  
312 *B. abortus* we constructed a deletion mutant and evaluated the intracellular replication  
313 capacity of the strain. Our results showed that the mutant had a defect in the early  
314 stages of the intracellular replication curve and that this alteration was the  
315 consequence of a reduced capacity to avoid the fusion of the BCV with the  
316 lysosomes. Interestingly, even though the mutant did not display any defects in its  
317 invasion it was significantly higher than that of the parental wild type strain.  
318 Consistently, the same observation was seen for the *virB10* polar mutant. These  
319 results are, apparently, inconsistent with the reduced viable bacteria at 1, 2, 3 and 4  
320 hrs post-infection. One hypothesis could be proposed here. Because it has been  
321 established that the route of entry in phagocytes can influence the final destination of  
322 the phagosome generated (Aderem *et al.*, 1999), it could be possible that SepA is  
323 involved in the initial steps of the intracellular life cycle facilitating certain routes that  
324 will ultimately influence the initial composition and final destination of the BCV. In  
325 this model the type IV secretion system and some effectors would be involved in the  
326 very early stages of the intracellular life cycle selecting the internalization route of the  
327 bacterium. Even though the mutant is more invasive than the parental wild type strain,  
328 the BCV generated in the process are less efficient for evading the early phagosome-  
329 lysosome fusion. Mechanistically, this process could be either through a positive or a



330 negative selection, this is SepA could facilitate phagocytosis through certain routes or  
331 inhibit others. We speculate that *sepA* participates in this early selection process and  
332 that its biological activity modifies the final destination of the BCV. At this stage the  
333 molecular mechanism used by SepA to promote infection is not known and the fact  
334 that the protein has no significant homology to any known proteins complicates this  
335 task significantly. Albeit the fact that a molecular mechanism is still lacking, to our  
336 knowledge this is the first Type IV secretion substrate in *Brucella* that shows a  
337 phenotype in cells altering the kinetics of Lamp-1 acquisition and exclusion.

338

339

340

341

## 342 **EXPERIMENTAL PROCEDURES**

343

### 344 **Bacterial strains and growth conditions**

345 *B. melitensis* biovar abortus 2308 was used as a wild-type strain. *B. abortus* strains  
346 were cultured in Tryptic Soy Agar (TSA; Difco/Becton-Dickinson, Sparks, MD), or  
347 in Tryptic Soy Broth (TSB) at 37°C on a rotary shaker for 16–24 hrs. When needed,  
348 media were supplemented with 50µg/ml Kanamycin (Km<sup>r</sup>), 5µg/ml Nalidixic Acid  
349 (Nal<sup>r</sup>), 100µg/ml Ampicillin (Amp<sup>r</sup>) or 3µg/ml Gentamicin (Gm<sup>r</sup>). Work with *B.*  
350 *abortus* was performed at the Biosafety Level 3 laboratory facility at the University of  
351 San Martín. *E. coli* strains were grown on Luria-Bertani (LB) agar and broth at 37°C  
352 overnight. Antibiotics, when required, were added at the following concentrations: 50  
353 µg/ml Kanamycin or 100 µg/ml Ampicillin.

### 354 **Recombinant DNA techniques**

355 To generate plasmid pBBR1-MCS4-3xFlag, a fragment containing a 3xFLAG epitope  
356 was amplified from plasmid pBAD24-3xFLAG (Spano *et al.*, 2008) using primers  
357 CC7-Flag (5'-CGCGGATCCACTCTAGAGATCGTCATCCTTGTA-3') and  
358 pbad/HindIII (5'-CCCAAGCTTGTCTCCATACCCGTTT-3'). The product was  
359 digested with BamHI-HindIII, and ligated into the same sites of plasmid pBBR1-  
360 MCS4 (Kovach *et al.*, 1995).

361 For the construction of vectors expressing a C-terminal 3xFLAG-tagged version of  
362 genes Bab1\_1492, Bab1\_0296, Bab1\_0752, Bab1\_0740, Bab1\_0745, the plasmid  
363 pBBR1-MCS4-3xFLAG was used. DNA fragments were amplified by PCR from *B.*  
364 *abortus* 2308 genomic DNA using primers F1492 (5'-  
365 CGGAATTCTTGAGCGGAGAGAGCC-3') and R1492 (5'-  
366 CGCCATGGCGGCGGACGCCGGGCC-3') for the Bab1\_1492 gene; F0296 (5'-

367 CGGAATTCTGAGACATGCGAATTAAG-3') and R0296 (5'-  
368 CGCCATGGCAAGCTCCAAGCATCTAAT-3') for the Bab1\_0296 gene; F0752  
369 (5'-TAGCTAGCTGTTCGCGGAAGTCAGCC-3') and R0752 (5'-  
370 GCCATGGCTAGGCGTCCAGACATTC-3') for the Bab1\_0752 gene; F0740 (5'-  
371 CGGAATTCTTTTGGTCGCTACGCGT-3')- and R0740 (5'-  
372 CGCCATGGCGAATTTGTCTAGCAGGT-3') for the Bab1\_0740 gene and F0745  
373 (5'-CGGAATTCAAATCAACGTTCAAATCTATC-3') and R0745 (5'-  
374 CGCCATGGCATATTCCAAAATATTCCTTTG-3') for the Bab1\_0745 gene. The  
375 truncated version (amino acids 25 to190) of Bab1\_1492 was generated, using primers  
376 FsNH2-1492 (5'-GGAATTCAGAGAGGGATGACCCCGAGCGAAACCATT-3')  
377 and R1492 (5'-CGCCATGGCGGCGGACGCCGGGCC-3'). All the PCR products  
378 were digested with EcoRI-NcoI, except the fragment 0752 that was digested with  
379 EcoRI-NheI. The resulting fragments were cloned in pBBR1-MCS4-3xFlag in the  
380 same sites generating in frame fusions to the 3xFLAG epitope. The resulting  
381 plasmids were named pBBR1-MCS4/ F2-3xF (Bab1\_1492), pBBR1-MCS4/ F2NH2-  
382 3xF (truncated version of Bab1\_1492), pBBR1-MCS4/ 0296-3xF (Bab1\_0296),  
383 pBBR1-MCS4/ 0752-3xF (Bab1\_0752), PBBR1-MCS4/ 0740-3xF (Bab1\_0740) and  
384 pBBR1-MCS4/ 0745-3xF (Bab1\_0745). Plasmids expressing 3xFLAG tagged fusion  
385 proteins were introduced in *B. abortus* strains by biparental mating. The integrity of  
386 all constructs was confirmed by sequence analysis.  
387 A *B. abortus*  $\Delta$ sepA strain with a clean deletion of Bab1\_1492 was constructed by  
388 standard recombinant DNA and allelic exchange procedures as previously described  
389 (Czibener *et al.*, 2012). The flanking regions of Bab1\_1492 were amplified by PCR  
390 using primers Del1492-1 (5'-CGGGATCCAGTTTCGCAGACGCGGTCCA-3'),  
391 Del1492-2 (5'-TATTCTCTCGTTGACCGCAA-3'), Del1492-3 (5'-

392 GTCAACGAGAGAATACTTCCTGTTTCGAAGCCGTTT-3') and Del1492-4 (5'-  
393 CCCAAGCTTTGAGCGGCCATTGCGTCAGG-3'). The PCR products were ligated  
394 using the recombinant PCR technique (Czibener *et al.*, 2012), and the resulting DNA  
395 fragment digested with BamHI-HindIII and ligated to the same sites of suicide vector  
396 pK18mobsacB, giving rise to plasmid pK18mobsacB/ $\Delta$ sepA. The plasmid was  
397 introduced in *B. abortus* strain by biparental mating, and the mutants Km<sup>s</sup> and Suc<sup>R</sup>  
398 were confirmed by colony PCR with primers Del1492-1 and Del1492-4.

### 399 **Intracellular replication curves**

400 Gentamicin protection assays were performed as previously described (Ugalde *et al.*,  
401 2000). All tissue cultures were maintained at 37°C in a humidified atmosphere  
402 containing 5% CO<sub>2</sub>. HeLa and J774.A1 macrophage-like cell lines were maintained in  
403 Dulbecco modified Eagle medium (Gibco Life Technologies) and RPMI 1640 (Gibco  
404 Life technologies), respectively, supplemented with 5% fetal bovine serum (PAA  
405 lab's GmbH, Pasching, Austria) and Streptomycin (50 µg/ml)/Penicillin (50 U/ml)  
406 (Gibco Life technologies). Cells were trypsinized, counted and seeded on 24-well  
407 plates in media, at a density of 5 x 10<sup>4</sup> cells per well, and were grown for 24 hrs. *B.*  
408 *abortus* infections were carried out at a multiplicity of infection (MOI) of 500:1 for  
409 HeLa cells and 100:1 for J774.A1 cells. Bacteria were centrifuged onto cells at 400  
410 × g for 10 min. After 60 min wells were gently washed three times with phosphate-  
411 buffered saline (PBS) and incubated for 3 hrs with fresh medium containing 50 µg/ml  
412 Gentamicin to kill non-internalized bacteria. At 4 hrs post-infection, cells were  
413 washed three times with PBS, and fresh medium containing 10 µg/ml Gentamicin was  
414 added. Bone marrow derived macrophages (BMDM) were prepared as described in  
415 (Czibener *et al.*, 2006). At the indicated times, infected cells were either washed three  
416 times with PBS and lysed with 500 µl 0.1% Triton X-100 in H<sub>2</sub>O (Sigma-Aldrich) or

417 processed for immunofluorescence staining as described below. The intracellular  
418 CFU counts were determined by plating serial dilutions on TSA with the appropriate  
419 antibiotics.

#### 420 **Antibodies and reagents**

421 All the antibodies were diluted in 10% horse serum (Gibco), 5% BSA (Sigma) and  
422 0.1% saponin (Sigma), except for the anti-FLAG M2 monoclonal antibody (Sigma),  
423 that was diluted in 0.2 % Triton X-100 instead of 0.1% saponin for cell  
424 permeabilization. The primary antibodies used were rabbit anti-*Brucella* polyclonal  
425 antibody (1:1,500), mouse immunoglobulin G anti-O-antigen monoclonal antibody  
426 M-84 (1:1000) (Nielsen *et al.*, 1995), mouse anti-human LAMP-1 H4A3 (1:400)  
427 (Developmental Studies Hybridoma Bank, Department of Biological Sciences,  
428 University of Iowa), and mouse anti-FLAG M2 monoclonal antibody (1:4000). The  
429 secondary antibodies used were Alexa Fluor 488 goat anti-rabbit or anti-mouse and  
430 Alexa Fluor 568 goat anti-rabbit or anti-mouse (Molecular Probes, Invitrogen Co.).  
431 For DNA staining, DAPI dye at 2 µg/ml (final concentration) was used.

#### 432 **Immunofluorescence microscopy**

433 Eukaryotic cells were plated on glass coverslips (Marienfeld GmbH & co. KG) and  
434 infected as described above. For HeLa cells the MOI was 1000:1, and for J774.A1  
435 cells the MOI was 500:1. At the indicated times, the coverslips were washed with  
436 PBS and the cells were fixed for 15 min in 4% paraformaldehyde (pH 7.4) at room  
437 temperature. After fixation, cells were washed three times with PBS and incubated for  
438 10 min with PBS-50 mM NH<sub>4</sub>CL in order to quench free aldehyde groups. For the  
439 In/Out assay, the coverslips were incubated with rabbit anti-*Brucella* antibody for 45  
440 min at room temperature, washed in PBS and incubated for 30 min with PBS-10%  
441 horse serum-5% BSA-0.1% saponin permeabilization solution. Then washed in PBS,

442 and incubated for 45 min with mouse anti-O-antigen antibody M-84. After the second  
443 antibody the cells were washed with PBS and incubated for 45 min with Alexa Fluor  
444 568 goat anti-rabbit, Alexa Fluor 488 goat anti-mouse secondary antibodies and the  
445 DAPI dye.

446 For the Lamp-1 co-localization assay, coverslips were incubated for 30 min with  
447 PBS-10% horse serum-5% BSA-0.1% saponin permeabilization solution, washed  
448 with PBS, and incubated for 45 min with mouse anti-human Lamp-1 H4A3 antibody.  
449 After 5 washes with PBS, they were incubated for 45 min with rabbit anti-  
450 *Brucella* antibody, washed again with PBS, and then incubated for 45 min with Alexa  
451 Fluor 568 goat anti-rabbit and Alexa Fluor 488 goat anti-mouse secondary antibodies.

452 For the Screening assays, the coverslips were incubated for 30 min with PBS-10%  
453 horse serum-5% BSA-0.1% saponin permeabilization solution, washed with PBS, and  
454 incubated for 45 min with a rabbit anti-*Brucella* antibody. After 5 washes with PBS,  
455 cells were incubated for 30 min with PBS-10% horse serum-5% BSA- 0.2% Triton X-  
456 100 permeabilization solution, washed again with PBS and incubated for 45 min with  
457 mouse anti-FLAG M2. Then washed with PBS, and finally incubated for 45 min with  
458 Alexa Fluor 568 goat anti-rabbit, Alexa Fluor 488 goat anti-mouse secondary  
459 antibodies and DAPI dye.

460 After immunofluorescence staining, all the coverslips were mounted onto slides with  
461 FluorSave (Calbiochem). Samples were examined on a Nikon microscope (Eclipse  
462 TE 2000) at a magnification of X600. The software MBF ImageJ v1.43m (Wayne  
463 Rasband, NIH, USA) was used to merge the microscopic images. Con-Focal images  
464 were acquired in an Olympus FV 1000 inverted microscope and images, as well as Z  
465 stacks, processed with the Fluoview FV100 software provided with the microscope.

466

467 **Mouse infections**

468 Mice infections were performed as previously described (Ugalde *et al.*, 2003). Groups  
469 of 5 eight to nine week-old female BALB/c mice were intraperitoneally inoculated  
470 with  $1 \times 10^5$  CFU of *B. abortus* 2308 wild type,  $\Delta sepA$ , complemented or SepA  
471 overexpressing strains in PBS. At 2 weeks post-infection, spleens from infected mice  
472 were removed and homogenized in 2 ml of PBS. Serial dilutions from individualized  
473 spleens were plated on TSA with the appropriate antibiotics to quantify recovered  
474 CFU.

475 **Periplasmic and cytoplasmic localization assay**

476 For the periplasmic localization assays the *B. abortus* strains were cultivated in TSB  
477 for 16h - 24h at 37°C until an  $OD_{600nm}$  1 was reached  $2.5 \times 10^{10}$  bacterial cells were  
478 centrifuged 10 min at 3300xg. The pellets were washed with physiologic solution,  
479 centrifuged for 10 min at 3300xg and resuspended in 1 ml of 0.2M Tris-HCl pH 7.6.  
480 1 ml of 0.2M Tris-HCl pH 7.6, 1M Sucrose and 0.25% Zwitterion 3-16 solution was  
481 added to the cell suspension and incubated for 10 min at room temperature. The  
482 samples were centrifuged for 30 min at 8000xg, the pellets separated from the  
483 supernatants and stored at -20°C until used. The pellets and supernatants were  
484 processed for Western-Blot, using an anti-FLAG M2 monoclonal antibody (1:5000),  
485 anti GroEL (1:2000) and anti OMP-1 (1:2000) kindly provided by Dr. Axel  
486 Cloeckert as primary antibodies, and goat anti-mouse HRP (1:2000) (Dako) as  
487 secondary antibody. All antibodies were diluted in Tris-buffered saline (TBS)- 5%  
488 non-fat milk- 0.05% Tween solution.

489

490

491

492 **Acknowledgments**

493 The authors declare no conflict of interest.

494 We thank Pablo Dosantos and Francisco Guaimas for confocal microscopy assistance.

495 This work was supported by grants PICT-PRH08-160 and PICT-PRH08-230 to C.C.

496 and J.E.U. respectively, NIAID grant AI078891 to J.E.U., and grants from the

497 University of San Martín to C.C. and J.E.U. P.H.D and E.V. were supported by

498 fellowships of the National Research Council of Argentina (CONICET). CC and

499 J.E.U. are members of the CONICET.

500

501

502 **REFERENCES**

503

504 Aderem, A. and Underhill, D.M. (1999). Mechanisms of phagocytosis in  
505 macrophages. *Annu Rev Immunol* 17, 593-623.

506 Alvarez-Martinez, C.E. and Christie, P.J. (2009). Biological diversity of  
507 prokaryotic type IV secretion systems. *Microbiol Mol Biol Rev* 73, 775-  
508 808.

509 Arocena, G.M., Sieira, R., Comerci, D.J. and Ugalde, R.A. (2010). Identification  
510 of the quorum-sensing target DNA sequence and N-Acyl homoserine  
511 lactone responsiveness of the *Brucella abortus* virB promoter. *J Bacteriol*  
512 192, 3434-3440.

513 Arocena, G.M., Zorreguieta, A. and Sieira, R. (2012). Expression of VjbR under  
514 nutrient limitation conditions is regulated at the post-transcriptional level  
515 by specific acidic pH values and urocanic acid. *PLoS One* 7, e35394.

516 Atluri, V.L., Xavier, M.N., de Jong, M.F., den Hartigh, A.B. and Tsolis, R.E.  
517 (2011). Interactions of the human pathogenic *Brucella* species with their  
518 hosts. *Annu Rev Microbiol* 65, 523-541.

519 Burns, D.L. (2003). Type IV transporters of pathogenic bacteria. *Curr Opin*  
520 *Microbiol* 6, 29-34.

521 Celli, J., de Chastellier, C., Franchini, D.M., Pizarro-Cerda, J., Moreno, E. and  
522 Gorvel, J.P. (2003). *Brucella* evades macrophage killing via VirB-  
523 dependent sustained interactions with the endoplasmic reticulum. *J Exp*  
524 *Med* 198, 545-556.

525 Celli, J., Salcedo, S.P. and Gorvel, J.P. (2005). *Brucella* coopts the small GTPase  
526 Sar1 for intracellular replication. *Proc Natl Acad Sci U S A* 102, 1673-  
527 1678.



- 528 **Comerci, D.J., Martinez-Lorenzo, M.J., Sieira, R., Gorvel, J.P. and Ugalde, R.A.**  
529 **(2001). Essential role of the VirB machinery in the maturation of the**  
530 **Brucella abortus-containing vacuole. *Cell Microbiol* 3, 159-168.**
- 531 **Corbel, M.J. (1997). Brucellosis: an overview. *Emerg Infect Dis* 3, 213-221.**
- 532 **Cossart, P. and Roy, C.R. (2010). Manipulation of host membrane machinery by**  
533 **bacterial pathogens. *Curr Opin Cell Biol* 22, 547-554.**
- 534 **Czibener, C., Sherer, N.M., Becker, S.M., Pypaert, M., Hui, E., Chapman, E.R.,**  
535 ***et al.* (2006). Ca<sup>2+</sup> and synaptotagmin VII-dependent delivery of**  
536 **lysosomal membrane to nascent phagosomes. *J Cell Biol* 174, 997-1007.**
- 537 **Czibener, C. and Ugalde, J.E. (2012). Identification of a unique gene cluster of**  
538 **Brucella spp. that mediates adhesion to host cells. *Microbes Infect* 14, 79-**  
539 **85.**
- 540 **de Barsy, M., Jamet, A., Filopon, D., Nicolas, C., Laloux, G., Rual, J.F., *et al.***  
541 **(2011). Identification of a Brucella spp. secreted effector specifically**  
542 **interacting with human small GTPase Rab2. *Cell Microbiol* 13, 1044-1058.**
- 543 **de Jong, M.F., Sun, Y.H., den Hartigh, A.B., van Dijk, J.M. and Tsolis, R.M.**  
544 **(2008). Identification of VceA and VceC, two members of the VjbR**  
545 **regulon that are translocated into macrophages by the Brucella type IV**  
546 **secretion system. *Mol Microbiol* 70, 1378-1396.**
- 547 **Del Giudice, M.G., Ugalde, J.E. and Czibener, C. (2013). A lysozyme-like protein**  
548 **in Brucella abortus is involved in the early stages of intracellular**  
549 **replication. *Infect Immun* 81, 956-964.**
- 550 **Delrue, R.M., Deschamps, C., Leonard, S., Nijskens, C., Danese, I., Schaus, J.M.,**  
551 ***et al.* (2005). A quorum-sensing regulator controls expression of both the**  
552 **type IV secretion system and the flagellar apparatus of Brucella**  
553 **melitensis. *Cell Microbiol* 7, 1151-1161.**
- 554 **Godfroid, J., Scholz, H.C., Barbier, T., Nicolas, C., Wattiau, P., Fretin, D., *et al.***  
555 **(2011). Brucellosis at the animal/ecosystem/human interface at the**  
556 **beginning of the 21st century. *Prev Vet Med* 102, 118-131.**
- 557 **Kovach, M.E., Elzer, P.H., Hill, D.S., Robertson, G.T., Farris, M.A., Roop, R.M.,**  
558 **2nd and Peterson, K.M. (1995). Four new derivatives of the broad-host-**  
559 **range cloning vector pBBR1MCS, carrying different antibiotic-resistance**  
560 **cassettes. *Gene* 166, 175-176.**
- 561 **Marchesini, M.I., Herrmann, C.K., Salcedo, S.P., Gorvel, J.P. and Comerci, D.J.**  
562 **(2011). In search of Brucella abortus type IV secretion substrates:**  
563 **screening and identification of four proteins translocated into host cells**  
564 **through VirB system. *Cell Microbiol* 13, 1261-1274.**
- 565 **Myeni, S., Child, R., Ng, T.W., Kupko, J.J., 3rd, Wehrly, T.D., Porcella, S.F., *et***  
566 ***al.* (2013). Brucella Modulates Secretory Trafficking via Multiple Type IV**  
567 **Secretion Effector Proteins. *PLoS Pathog* 9, e1003556.**
- 568 **Nagai, H. and Roy, C.R. (2001). The DotA protein from Legionella pneumophila**  
569 **is secreted by a novel process that requires the Dot/Icm transporter.**  
570 ***EMBO J* 20, 5962-5970.**
- 571 **Nielsen, K.H., Kelly, L., Gall, D., Nicoletti, P. and Kelly, W. (1995). Improved**  
572 **competitive enzyme immunoassay for the diagnosis of bovine brucellosis.**  
573 ***Vet Immunol Immunopathol* 46, 285-291.**
- 574 **Ninio, S. and Roy, C.R. (2007). Effector proteins translocated by Legionella**  
575 **pneumophila: strength in numbers. *Trends Microbiol* 15, 372-380.**
- 576 **O'Callaghan, D., Cazeville, C., Allardet-Servent, A., Boschioli, M.L., Bourg,**  
577 **G., Foulongne, V., *et al.* (1999). A homologue of the Agrobacterium**

578 tumefaciens VirB and Bordetella pertussis Ptl type IV secretion systems is  
579 essential for intracellular survival of Brucella suis. *Mol Microbiol* 33,  
580 1210-1220.

581 Pantoja, M., Chen, L., Chen, Y. and Nester, E.W. (2002). Agrobacterium type IV  
582 secretion is a two-step process in which export substrates associate with  
583 the virulence protein VirJ in the periplasm. *Mol Microbiol* 45, 1325-1335.

584 Pizarro-Cerda, J., Desjardins, M., Moreno, E., Akira, S. and Gorvel, J.P. (1999).  
585 Modulation of endocytosis in nuclear factor IL-6(-/-) macrophages is  
586 responsible for a high susceptibility to intracellular bacterial infection. *J*  
587 *Immunol* 162, 3519-3526.

588 Pizarro-Cerda, J., Meresse, S., Parton, R.G., van der Goot, G., Sola-Landa, A.,  
589 Lopez-Goni, I., *et al.* (1998). Brucella abortus transits through the  
590 autophagic pathway and replicates in the endoplasmic reticulum of  
591 nonprofessional phagocytes. *Infect Immun* 66, 5711-5724.

592 Rutherford, K., Parkhill, J., Crook, J., Horsnell, T., Rice, P., Rajandream, M.A.  
593 and Barrell, B. (2000). Artemis: sequence visualization and annotation.  
594 *Bioinformatics* 16, 944-945.

595 Sieira, R., Arocena, G.M., Bukata, L., Comerci, D.J. and Ugalde, R.A. (2010).  
596 Metabolic control of virulence genes in Brucella abortus: HutC  
597 coordinates virB expression and the histidine utilization pathway by  
598 direct binding to both promoters. *J Bacteriol* 192, 217-224.

599 Sieira, R., Arocena, G.M., Zorreguieta, A., Comerci, D.J. and Ugalde, R.A.  
600 (2012). A MarR-Type Regulator Directly Activates Transcription from  
601 the Brucella abortus virB Promoter by Sharing a Redundant Role with  
602 HutC. *J Bacteriol* 194, 6431-6440.

603 Sieira, R., Comerci, D.J., Pietrasanta, L.I. and Ugalde, R.A. (2004). Integration  
604 host factor is involved in transcriptional regulation of the Brucella  
605 abortus virB operon. *Mol Microbiol* 54, 808-822.

606 Sieira, R., Comerci, D.J., Sanchez, D.O. and Ugalde, R.A. (2000). A homologue of  
607 an operon required for DNA transfer in Agrobacterium is required in  
608 Brucella abortus for virulence and intracellular multiplication. *J Bacteriol*  
609 182, 4849-4855.

610 Spano, S., Ugalde, J.E. and Galan, J.E. (2008). Delivery of a Salmonella Typhi  
611 exotoxin from a host intracellular compartment. *Cell Host and Microbe* In  
612 press.

613 Ugalde, J.E., Comerci, D.J., Leguizamon, M.S. and Ugalde, R.A. (2003).  
614 Evaluation of Brucella abortus phosphoglucomutase (pgm) mutant as a  
615 new live rough-phenotype vaccine. *Infect Immun* 71, 6264-6269.

616 Ugalde, J.E., Czibener, C., Feldman, M.F. and Ugalde, R.A. (2000).  
617 Identification and characterization of the Brucella abortus  
618 phosphoglucomutase gene: role of lipopolysaccharide in virulence and  
619 intracellular multiplication. *Infect Immun* 68, 5716-5723.

620  
621  
622

623

## 624 LEGENDS TO FIGURES

625

626 **Figure 1. The protein product of Bab1\_1492 is secreted during the infection of**

627 **host cells. A.** Schematic representation of the screening method used to identify novel

628 secreted virulence effectors in *Brucella abortus*. **B.** Immunofluorescence of J774 A.1

629 cells infected with a *B. abortus* strain coding for Bab1\_1492-3xFLAG in a replicative

630 vector at 4 hrs post-infection. Red, *Brucella*; green, Flag. **C.** Immunofluorescence of

631 J774 A.1 cells infected with a *B. abortus* strain coding for Bab1\_0740-3xFLAG in a

632 replicative vector at 4 hrs post-infection. Red, *Brucella*; green, Flag. **D.** Western-blot

633 with an anti-FLAG of the strains shown in panels B and C.

634

635 **Figure 2. Confocal analysis of the secretion of the protein product of Bab1\_1492.**

636 Confocal images of J774 A.1 cells infected with the *B. abortus* strains coding for

637 Bab1\_1492-3xFLAG (**A**) or Bpe123-3xFLAG (**B**) in replicative vectors at 4 hrs post-

638 infection. **C.** A 45° rotation view of the line traced in the inset of panel A. **D.**

639 Quantification of the red and green fluorescence intensity over the line traced in the

640 inset of panel A showing a correlation between both markers. Red, *Brucella*; green,

641 FLAG.

642

643 **Figure 3. Secretion of SepA is a *virB* dependent process. A.** Representative

644 Immunofluorescence of J774 A.1 cells infected with *B. abortus* wild type, *virB10* and

645  $\Delta$ *virB11* mutant strains coding for SepA-3xFLAG in a replicative vector at 4 hrs post-

646 infection. Red, *Brucella*; green, FLAG. **B.** Quantification of the percent of SepA

647 secreting bacteria of the representative images shown in A. \*  $P < 0.05$ . **C.** Western-

648 blot with an anti-FLAG of the strains showing equivalent levels of expression of  
649 SepA.

650

651 **Figure 4. Secretion of SepA involves a periplasmic intermediate. A.** Western-blot  
652 with an anti-FLAG, anti-GroEL and anti OMP1 monoclonal antibodies of periplasmic  
653 or cytoplasmic fractions of a periplasmic fractionation assay performed with *B.*  
654 *abortus* chromosomal Bab2\_0448-3xFLAG tagged strain carrying the plasmid coding  
655 for SepA-3xFLAG. Schematic representation of the  $\Delta$ N-SepA-3xFLAG ( $\Delta$ N-SepA)  
656 construction carrying a N-terminal 25 amino acid deletion. **B.** Immunofluorescence of  
657 J774 A.1 cells infected with *B. abortus* strains carrying plasmids coding for SepA-  
658 3xFLAG (SepA) or  $\Delta$ N-SepA-3xFLAG ( $\Delta$ N-SepA) at 4 hrs post-infection. Red,  
659 *Brucella*; green, FLAG. **C.** Western-blot showing the expression levels of SepA and  
660  $\Delta$ N-SepA in Wild-type *B. abortus*. Loading control, OMP1. **D.** Western-blot with an  
661 anti-FLAG, anti-GroEL and anti OMP1 monoclonal antibodies of periplasmic or  
662 cytoplasmic fractions of a periplasmic fractionation assay performed with *B. abortus*  
663 *virB10* and *virB11* mutant strains carrying the plasmid coding for SepA-3xFLAG.

664

665 **Figure 5. SepA participates in the early stages of intracellular replication. A.**  
666 Intracellular replication of *B. abortus* wild type and  $\Delta$ sepA deletion strains in HeLa  
667 cells determined by the gentamicin protection assay. **B.** Intracellular replication of *B.*  
668 *abortus* wild type and  $\Delta$ sepA deletion strains in J774 A.1 cells determined by the  
669 gentamicin protection assay. **C.** Intracellular replication of *B. abortus* wild type and  
670  $\Delta$ sepA deletion strains in bone marrow derived macrophages determined by the  
671 gentamicin protection assay **D.** Viable bacteria of the wild type (*Ba wt*), *Ba*  $\Delta$ sepA  
672 mutant and complemented strains at 4 hrs post-infection measured by an antibiotic

673 protection assay in J774 A.1 cells with different multiplicity of infection ratios (50,  
674 100 and 500). **E.** Growth curve of the wild type and the  $\Delta sepA$  deletion strain in TSB.  
675 **F.** Complementation of the 4 hrs phenotype with the construction lacking the N-  
676 terminal periplasmic localization signal. \*\* $P < 0.002$  and \*\*\* $P < 0.001$ .

677

678 **Figure 6. The  $\Delta sepA$  mutant strain invades cells more efficiently. A and B.** In/out  
679 staining of the wild type strain (*Ba wt*) and the  $\Delta sepA$  (*Ba  $\Delta sepA$* ) mutant strain  
680 respectively at 1 hr post-infection in J774 A.1 cells. **C.** Quantification of the  
681 immunofluorescence shown in panels A and B. *Ba virB10*, assay performed with the  
682 *B. abortus virB10* mutant. \*\* $P < 0.002$ . **D.** Intracellular viable bacteria of the wild type  
683 mutant and complemented strains at 1, 2, 3 and 4 hrs post-infection determined by an  
684 antibiotic protection assay. \* $P < 0.001$ .

685

686 **Figure 7. The  $\Delta sepA$  mutant strain is affected in its capacity to exclude the**  
687 **lysosomal marker Lamp-1. A.** Representative immunofluorescence images of  
688 Lamp-1 positive and negative BCVs of the wild type (*Ba wt*) and mutant (*Ba  $\Delta sepA$* )  
689 strains in infected HeLa cells at 24 hours post-infection. Red, *Brucella*; green, Lamp-  
690 1. **B.** Quantification of the percent of Lamp-1 positive BCVs at 4 and 24 hrs post-  
691 infection with the wild type and the  $\Delta sepA$  mutant strains.

692

693 **Figure 8. Over-expression of SepA affects virulence in mice. A and B.** Spleen  
694 colonization at 15 days post-infection of mice intraperitoneally infected with the wild  
695 type (*Ba wt*), *sepA* mutant (*Ba  $\Delta sepA$* ), complemented (*Ba  $\Delta sepA(sepA)$* ) or SepA  
696 over-expressing (*Ba wt(sepA)*) strains. Bacterial load was determined as indicated in  
697 Experimental procedures. \* $P < 0.002$ . **C.** Western-blot with a monoclonal anti-O-

698 antigen antibody (M84) against whole bacteria showing that neither the mutant nor  
699 the over-expressing strains are rough.


700

701


702

**A** *B. abortus* genome → Identification of recombinases or transposases adjacent to tRNAs → 6 potential regions  
69 potential genes


Bab1\_0296  
Bab1\_0740  
Bab1\_0745 ← 4 potential regions  
Bab1\_0752  
Bab1\_1492  
5 potential genes




**B**







**C**



**D**




cm\_i\_12224\_fl.eps






A



B



C












Figure 3



**Figure 4**



**A****B****C****D****E****F****Figure 5**

cmi\_12224\_f5.eps




**Figure 6**

cmi\_12224\_f6.eps



**Figure 7**



**Figure 8**